Merck and Eisai's Keytruda/Lenvima combo fails PhIII trials for melanoma, colorectal cancer
Since 2018 — when Merck and Eisai kicked off their collaboration to combine and test out Keytruda and Lenvima against multiple cancers — the two-drug combo has been approved in advanced renal cell carcinoma and certain types of advanced endometrial carcinoma.
But as Merck continues on its quest to grow Keytruda’s blockbuster status ahead of a 2028 patent cliff, it hasn’t been all good news. Adding to the disappointment column, the companies reported two Phase III fails in unresectable or metastatic melanoma and unresectable and metastatic colorectal cancer last week in the LEAP clinical program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.